Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund intends to invest in groundbreaking therapeutic approaches and technologies.
Business Model:
Revenue: $6.6M
Employees: 51-200
Rankings
Industries / Tags:
Detailed Boehringer Ingelheim Venture Fund Information
Geographic Data
Address: Binger Strasse 173
City: Ingelheim am Rhein
State: rhineland-palatinate
Zip: 55216
Country: DE
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Boehringer Ingelheim Venture Fund GmbH (BIVF) invests in groundbreaking therapeutics-focused biotechnology companies to drive innovation in biomedical research. BIVF is searching for significant enhancements in patient care through pioneering science and its clinical translation by building long-term relationships with scientists and entrepreneurs. BIVF’s focus is to target unprecedented therapeutic concepts addressing high medical needs in immuno-oncology, regenerative medicine, infectious diseases and digital health. These may include novel platform technologies to address so far undruggable targets, new generation vaccines and/or new biological entities, such as oncolytic virotherapy.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 8/2020 | T-knife | Series A | 78.4M |
| 12/2016 | Acousia Therapeutics | Series A | 0 |
| 4/2020 | Rgenta Therapeutics | Seed Round | 20M |
| 10/2014 | Rigontec | Series A | 12M |
| 6/2021 | xCures | Series A | 0 |
| 10/2021 | Optina Diagnostics | Series A | 0 |
| 11/2013 | Hookipa Pharma | Series B | 27M |
| 3/2021 | Delonix Bioworks | Seed Round | 14M |
| 12/2019 | Metabomed | Series B | 0 |
| 3/2022 | ArrePath | Seed Round | 0 |
| 6/2019 | Viron | Series A | 25M |
| 5/2019 | Rinri Therapeutics | Seed Round | 1.8M |
| 12/2021 | Brainomix | Series B | 0 |
| 1/2020 | Eyevensys | Series B | 30M |
| 11/2012 | ArmaGen Technologies | Series A | 0 |
| 11/2016 | NBE-Therapeutics | Series B | 20.5M |
| 9/2010 | Okairos | Series B | 20.5M |
| 6/2015 | Vira Therapeutics | Series A | 4M |
| 12/2017 | Hookipa Pharma | Series C | 0 |
| 10/2020 | Topas Therapeutics | Series B | 0 |
| 9/2020 | Libra Therapeutics | Series A | 29M |
| 9/2019 | Tacalyx | Seed Round | 7.7M |
| 5/2017 | ImCheck Therapeutics | Series A | 21.9M |
| 5/2017 | Cardior Pharmaceuticals | Series A | 16.3M |
| 5/2013 | STAT-Dx | Series B | 28.9M |
| 9/2020 | Ruipeng Pet Healthcare | Venture Round | - |
| 7/2020 | T3 Pharmaceuticals | Series C | 26.9M |
| 1/2023 | Rewind Therapeutics | Series A | - |
| 5/2018 | Acousia Therapeutics | Series B | 0 |
| 5/2020 | Wellth | Series A | 10M |
| 12/2016 | HepaRegeniX | Series A | 9.5M |
| 10/2021 | Abalos Therapeutics | Series A | 0 |
| 5/2023 | smartbax | Pre Seed Round | 0 |
| 4/2014 | Sentieon | Series A | 0 |
| 11/2022 | Rgenta Therapeutics | Series A | 0 |
| 4/2016 | Metabomed | Series A | 18M |
| 10/2016 | Promethera Biosciences | Series C | 10.9M |
| 4/2020 | Actym Therapeutics, Inc. | Series A | 34M |
| 4/2018 | Brainomix | Venture Round | 9.8M |
| 12/2021 | Viron | Series B | 50M |
| 3/2016 | eTheRNA immunotherapies | Series A | 26.6M |
| 1/2018 | Rewind Therapeutics | Series A | 18.3M |
| 9/2018 | Wellth | Seed | 5.1M |
| 12/2017 | Aelin Therapeutics | Series A | 31.8M |
| 3/2012 | Promethera Biosciences | Series B | 0 |
| 6/2018 | NBE-Therapeutics | Series B | 0 |
| 4/2016 | STAT-Dx | Series C | 0 |
| 5/2023 | DiogenX | Series A | 0 |
| 3/2015 | Rigontec | Series A | 5.2M |
| 12/2019 | ImCheck Therapeutics | Series B | 53.2M |
| 9/2022 | C-mo Medical Solutions | Seed Round | 4.1M |
| 9/2017 | Amal Therapeutics | Series B | 9.5M |
| 11/2018 | Amal Therapeutics | Series B | 32.6M |
| 8/2020 | Aignostics | Seed Round | 6M |
| 4/2019 | AgomAb Therapeutics | Series A | 23.6M |
| 6/2020 | DiogenX | Seed Round | 5.1M |
| 3/2021 | AgomAb Therapeutics | Series B | 0 |
| 10/2019 | Abalos Therapeutics | Series A | 0 |
| 9/2016 | Rigontec | Series A | 16.9M |
| 1/2023 | Rewind Therapeutics | Series B | - |
| 11/2017 | Topas Therapeutics | Series A | 4.7M |
| 12/2021 | OncoMyx Therapeutics | Series B | 0 |
| 3/2015 | NBE-Therapeutics | Series A | 3.1M |
| 1/2013 | NBE-Therapeutics | Seed Round | - |
| 11/2021 | Asgard Therapeutics | Seed Round | 0 |
| 6/2020 | eTheRNA immunotherapies | Series B | 0 |
| 12/2018 | T-knife | Seed Round | 9.1M |
| 6/2021 | Nuevocor | Series A | 0 |
| 7/2021 | Dopavision | Series A | 14.2M |
| 4/2017 | Sentien Biotechnologies | Series A | 12M |
| 8/2020 | Bodyport | Series A | 11.2M |
| 9/2022 | Aignostics | Series A | 0 |
| 1/2020 | HepaRegeniX | Series B | 12.2M |
| 6/2019 | Dopavision | Seed Round | 0 |
| 3/2016 | Amal Therapeutics | Series A | 3.1M |
| 12/2016 | Hookipa Pharma | Series B | 10.7M |
| 5/2023 | smartbax | Seed Round | 0 |
| 2/2022 | Centauri Therapeutics | Series A | 0 |
| 9/2019 | T3 Pharmaceuticals | Series B | 12.1M |
| 7/2021 | Topas Therapeutics | Series B | 0 |
| 6/2022 | ImCheck Therapeutics | Series C | 0 |
| 4/2013 | Eyevensys | Venture Round | - |
| 11/2020 | Perfood | Series A | 0 |
| 4/2021 | Rinri Therapeutics | Venture Round | 0 |
| 5/2023 | smartbax | Seed Round | 0 |
| 5/2023 | smartbax | Pre Seed Round | 0 |
| 5/2023 | DiogenX | Series A | 0 |
| 1/2023 | Rewind Therapeutics | Series A | - |
| 11/2022 | Rgenta Therapeutics | Series A | 0 |
| 9/2022 | Aignostics | Series A | 0 |
| 9/2022 | C-mo Medical Solutions | Seed Round | 0 |
| 6/2022 | ImCheck Therapeutics | Series C | 0 |
| 3/2022 | ArrePath | Seed Round | 0 |
| 2/2022 | Centauri Therapeutics | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
